Mani Mukta1, Priti Bala Sahay2. 1. Department of Obstetrics and Gynaecology, Rajendra Institute of Medical Sciences, Ranchi, India ; C/O: Dr. Arun Kumar, A-1, Aishwarya Residency, Argora Kathal More Road, Deepatoli, Pundag, Infront of Al-Rahmat Sun City, Ranchi, 834004 Jharkhand India. 2. Department of Obstetrics and Gynaecology, Rajendra Institute of Medical Sciences, Ranchi, India.
Abstract
OBJECTIVES: To compare oral misopostol 600 mcg with 10 IU units oxytocin i.m. in the active management of the third stage of labor. MATERIALS AND METHODS: A total of 200 pregnant women of 34-42 weeks of gestation delivering vaginally in the Rajendra Institute of Medical Sciences, Ranchi, were selected for study. Hundred women receivedoral misoprostol 600 mg and 100 women received i.m. oxytocin 10 IU immediately after delivery of the baby and cord clamping by the method of randomization. RESULTS: In the misoprostol group, mean blood loss is 145 ml, mean duration of the third stage of labor is 3.76 min, and mean fall in hemoglobin is 0.55 g/dl. In the oxytocin group, mean blood loss in 125.6 ml, mean duration of the third stage of labor in 3.50 min, and mean fall in hemoglobin is 0.48 g/dl. There was no significant difference between the two groups with regard to the above-mentioned factors. There were 8 cases of PPH in the misoprostol group and 6 cases in the oxytocin group. Twenty-two cases in the misoprostol group and 16 cases in the oxytocin group required additional oxytocics. Adverse effects like shivering and pyrexia were more in the misoprostol group. CONCLUSION:Oral misoprostol is as effective as oxytocin in AMTSL and can be used safely in vaginal deliveries for prevention of PPH, especially in non-institutional deliveries and in places of low resource settings.
RCT Entities:
OBJECTIVES: To compare oral misopostol 600 mcg with 10 IU units oxytocin i.m. in the active management of the third stage of labor. MATERIALS AND METHODS: A total of 200 pregnant women of 34-42 weeks of gestation delivering vaginally in the Rajendra Institute of Medical Sciences, Ranchi, were selected for study. Hundred women received oral misoprostol 600 mg and 100 women received i.m. oxytocin 10 IU immediately after delivery of the baby and cord clamping by the method of randomization. RESULTS: In the misoprostol group, mean blood loss is 145 ml, mean duration of the third stage of labor is 3.76 min, and mean fall in hemoglobin is 0.55 g/dl. In the oxytocin group, mean blood loss in 125.6 ml, mean duration of the third stage of labor in 3.50 min, and mean fall in hemoglobin is 0.48 g/dl. There was no significant difference between the two groups with regard to the above-mentioned factors. There were 8 cases of PPH in the misoprostol group and 6 cases in the oxytocin group. Twenty-two cases in the misoprostol group and 16 cases in the oxytocin group required additional oxytocics. Adverse effects like shivering and pyrexia were more in the misoprostol group. CONCLUSION: Oral misoprostol is as effective as oxytocin in AMTSL and can be used safely in vaginal deliveries for prevention of PPH, especially in non-institutional deliveries and in places of low resource settings.
Entities:
Keywords:
Active management of third stage of labor (AMTSL); Misoprostol; Oxytocin; Postpartum hemorrhage (PPH)
Authors: Richard J Derman; Bhalchandra S Kodkany; Shivaprasad S Goudar; Stacie E Geller; Vijaya A Naik; M B Bellad; Shobhana S Patted; Ashlesha Patel; Stanley A Edlavitch; Tyler Hartwell; Hrishikesh Chakraborty; Nancy Moss Journal: Lancet Date: 2006-10-07 Impact factor: 79.321
Authors: A M Gülmezoglu; J Villar; N T Ngoc; G Piaggio; G Carroli; L Adetoro; H Abdel-Aleem; L Cheng; G Hofmeyr; P Lumbiganon; C Unger; W Prendiville; A Pinol; D Elbourne; H El-Refaey; K Schulz Journal: Lancet Date: 2001-09-01 Impact factor: 79.321
Authors: Ioannis D Gallos; Helen M Williams; Malcolm J Price; Abi Merriel; Harold Gee; David Lissauer; Vidhya Moorthy; Aurelio Tobias; Jonathan J Deeks; Mariana Widmer; Özge Tunçalp; Ahmet Metin Gülmezoglu; G Justus Hofmeyr; Arri Coomarasamy Journal: Cochrane Database Syst Rev Date: 2018-04-25